Tatva Chintan Pharma Chem Limited

Chemicals · Chemicals & Petrochemicals

NSE: TATVA BSE: 543321
₹1784.20
▼ -22.20 (-1.23%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
66/100
Moderate
Valuation
38/100
Fairly Valued
Momentum
86/100
Bullish

QVM read Momentum-led Quality Moderate, Valuation Fairly Valued, Momentum Bullish

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹4,174 Cr
PE (TTM)
94.0
Industry median 24.4 (189 companies)
Price to Book
5.3
PEG (TTM)
0.1
Institutions holding %
7.04%
FII + DII, latest filed period
Piotroski Score
5
Relative return vs Nifty50, qtr %
64.5
Relative return vs Sector, qtr %
52.2
Free Cash Flow
₹-82 Cr
as of March 31, 2026
Industry median ₹-0 Cr (238 companies)
EPS Growth (YoY)
104.11%
as of June 30, 2026
Industry median 39.08% (220 companies)
Net Profit Growth (TTM)
1023.33%
as of June 30, 2026
Industry median 13.45% (212 companies)
Operating Revenue Growth (TTM)
39.82%
as of June 30, 2026
Industry median 7.93% (209 companies)
Profit Growth (YoY)
103.51%
as of June 30, 2026
Industry median 23.11% (213 companies)
Revenue Growth (YoY)
34.37%
as of June 30, 2026
Industry median 17.49% (205 companies)
Current Ratio
1.64
as of March 31, 2026
Industry median 1.87 (237 companies)
Debt to Equity
0.15
as of March 31, 2026
Industry median 0.16 (224 companies)
Interest Coverage
14.32
as of June 30, 2026
Industry median 8.97 (221 companies)
Net Margin
7.12%
as of June 30, 2026
Industry median 7.49% (212 companies)
Operating Margin (EBIT)
11.03%
as of June 30, 2026
Industry median 11.88% (214 companies)
Operating Margin (TTM)
12.12%
as of June 30, 2026
Industry median 9.75% (219 companies)
Return on Assets
4.19%
as of March 31, 2026
Industry median 4.33% (217 companies)
Return on Capital Employed
7.57%
as of March 31, 2026
Industry median 10.34% (218 companies)
Return on Equity
5.38%
as of March 31, 2026
Industry median 7.52% (219 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

4 of 8 met
  • Yes Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • Yes Debt to equity is below 0.5 (0.15)
  • No Return on equity is 15% or more (5.4%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

4 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

4 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • Yes Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-1.2%
Low 1776.1000 · High 1825.0000
1W return
0.3%
Low 1717.3000 · High 1880.0000
1M return
9.7%
Low 1520.0000 · High 1880.0000
52W return
73.5%
Low 1026.5000 · High 1880.0000
Lifetime High ₹2877.9500 (Nov. 2, 2021)
Lifetime Low ₹637.0000 (March 13, 2025)

Full price history and technicals →

EMA & SMA

Bullish6
Bearish0
5D
1777.3
10D
1754.2
20D
1720.6
50D
1644.8
100D
1536.8
200D
1361.1

Delivery and volume

Day avg. delivery
45.8%
Week avg. delivery
40.4%
Month avg. delivery
44.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1795.10
Pivot
First resistance1814.10
Second resistance1844.00
Third resistance1863.00
First support1765.20
Second support1746.20
Third support1716.30
Day RSI58.3
Day MFI68.1
Day MACD40.23
Day MACD signal30.91

Beta

1M2.92
3M1.72
1Y1.30
3Y0.75

Price change analysis

↑ 9.7%
Over 1 Month
LowHigh
1520.001880.00
↑ 50.1%
Over 3 Months
LowHigh
1177.001880.00
↑ 61.6%
Over 6 Months
LowHigh
1055.201880.00
↑ 73.5%
Over 1 Year
LowHigh
1026.501880.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 94.0 (own history: 62.9–4836.8)
Buy Zone
Revenue (June 30, 2026)
₹147 Cr
Net profit (June 30, 2026)
₹10 Cr
Basic EPS (June 30, 2026)
₹4.4700

Ranks #43 of 221 in Chemicals & Petrochemicals by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter72.02%
  • Mutual funds2.79%
  • FII/FPI3.93%
  • Other DII0.32%
  • Public20.94%

Largest holders

NameCategoryShares %Shares
Shekhar Rasiklal SomaniPromoter23.0700%5396861
Chintan Nitinkumar ShahPromoter20.9400%4897219
Ajay Mansukhlal PatelPromoter20.1600%4715345
Priti Ajay PatelPromoter3.8500%900000
Goldman Sachs Funds - Goldman Sachs India Equity PortfolioPublic2.5900%606662

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 72.02% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 3.82% to 3.93% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings decreased from 2.87% to 2.79% in Jun 2026 qtr

3 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 7 insider trades, 9 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
9 Feb 2026 Ajay Mansukhlal Patel Promoter Buy 0 ₹0
9 Feb 2026 Ajay Mansukhlal Patel (HUF) Promoter group Sell 0 ₹0
7 Sep 2023 Priti Ajay Patel Promoter group Sell 0 ₹0
7 Sep 2023 Ajay Mansukhlal Patel (HUF) Promoter group Sell 0 ₹0
7 Sep 2023 Ajay Mansukhlal Patel Promoter Sell 0 ₹0
7 Sep 2023 Shekhar Rasiklal Somani Promoter Sell 0 ₹0
7 Sep 2023 Darshana Nitinkumar Shah Promoter group Sell 0 ₹0

All insider and SAST disclosures →

DateClientDealActionQuantityPriceExchange
15 Oct 2025 MUSIGMA SECURITIES Bulk Sell 143,717 1262.5100 NSE
15 Oct 2025 MUSIGMA SECURITIES Bulk Buy 143,717 1262.1400 NSE
15 Oct 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 133,709 1212.7400 NSE
15 Oct 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 133,709 1210.8900 NSE
25 Jul 2025 MUSIGMA SECURITIES Bulk Sell 117,833 1171.3600 NSE
25 Jul 2025 MUSIGMA SECURITIES Bulk Buy 117,833 1170.7400 NSE
25 Jul 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Buy 217,066 1152.0800 NSE
25 Jul 2025 GRAVITON RESEARCH CAPITAL LLP Bulk Sell 217,066 1153.9200 NSE
6 Sep 2023 DAKSHA DUSHYANT PATEL Bulk Buy 124,000 1646.0300 BSE
6 Sep 2023 AJAY MANSUKHLAL PATEL HUF Bulk Sell 206,366 1642.1200 BSE

All bulk and block deals →

Last 12 months ₹2.00 per share
Dividend yield 0.11%
Ex-dateSubjectPer share (₹)Record date
11 Sep 2026 Dividend - Rs 2 Per Share 2.0000 11 Sep 2026
12 Sep 2025 Dividend - Re 1 Per Share 1.0000 12 Sep 2025
6 Sep 2024 Dividend - Rs 2 Per Share 2.0000 6 Sep 2024
8 Sep 2023 Dividend - Rs 2 Per Share 2.0000 8 Sep 2023
8 Sep 2022 Dividend - Rs 2 Per Share 2.0000 9 Sep 2022

Corporate Actions

Full history (9 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
6 Sep 2024OTHERAnnual General Meeting
8 Sep 2023OTHERAnnual General Meeting
8 Sep 2022OTHERAnnual General Meeting
17 Sep 2021OTHER Annual General Meeting

All corporate actions →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
17 Jul 2026 Financial Results Yes
16 May 2026 Financial Results/Dividend Yes
21 Jan 2026 Financial Results Yes
31 Oct 2025 Financial Results Yes
24 Jul 2025 Financial Results Yes

Corporate Announcements

All 455 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
26 Sep 2026 Shareholders meeting Tatva Chintan Pharma Chem Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 25, 2026. Further, the company has informed the Exchange regarding voting results.
25 Sep 2026 Shareholders meeting Tatva Chintan Pharma Chem Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 25, 2026
25 Sep 2026 AGM/EGM Tatva Chintan Pharma Chem Ltd - 543321 - Shareholder Meeting / Postal Ballot-Outcome of AGM
23 Sep 2026 Trading Window Tatva Chintan Pharma Chem Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
17 Sep 2026 Analysts/Institutional Investor Meet/Con. Call Updates Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet
8 Sep 2026 Company Update Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8 Sep 2026 Company Update Tatva Chintan Pharma Chem Ltd - 543321 - Announcement under Regulation 30 (LODR)-Credit Rating
8 Sep 2026 Analysts/Institutional Investor Meet/Con. Call Updates Tatva Chintan Pharma Chem Limited has informed the Exchange about Schedule of meet
8 Sep 2026 Credit Rating Tatva Chintan Pharma Chem Limited has informed the Exchange about Credit Rating
28 Aug 2026 Copy of Newspaper Publication Tatva Chintan Pharma Chem Limited has informed the Exchange about Copy of Newspaper Publication

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.15)
  • Comfortable interest coverage (14.3x)
  • Healthy liquidity (Current Ratio 1.64)
  • Strong revenue growth YoY (34.4%)

Weaknesses

  • Low Return on Equity (5.4%)

Opportunities

  • PEG below 1 (0.09) -- earnings growth outpacing its own valuation

Threats

  • PE above 35 (94.0) -- priced for continued strong execution

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Tatva Chintan Pharma Chem Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.